Reporter brief
Fisetin reduced complications in COVID-19 outpatients in a placebo-controlled pilot trial.
What happened
COVFIS-HOME tested whether fisetin, a senolytic drug, could reduce complications in COVID-19 patients. The phase 2 placebo-controlled pilot study enrolled at-risk outpatients, but the abstract does not report sample size, effect sizes, or specific findings on whether fisetin reduced complications.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Not recorded.
- Design
- Rct
- Sample
- —
- Journal
- James L. Kirkland, MD, PhD
- Published
- Aug 1, 2023
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.